ABSI

Absci Corporation
CAPPED RATING

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation (ABSI) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (F). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
F
Factor Score 0.0 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.7
EV / EBITDA -9.0
Rev Growth YoY -19.6%
Gross Margin 0.0%
Price Return 3M -15.5%
Price Return 12M 183.1%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue $1.5M
Price / Sales 868.4
ROE -58.6%

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 F (0.0) C+ (2.7) D (1.5) B (3.3) C+ (2.6) C- (2.0)
2026-11-10 F (0.0) C+ (2.7) D (1.5) B+ (3.7) C+ (2.6) C- (2.1)
2026-11-03 F (0.0) C+ (2.6) D (1.4) A- (4.0) C+ (2.7) C- (2.1)
2026-10-27 F (0.0) C+ (2.6) D (1.3) A (4.3) C+ (2.6) C (2.2)
2026-10-20 F (0.0) C+ (2.6) D (1.3) B+ (3.8) C+ (2.6) C- (2.1)
Page 1 of 8
…